Dyadic Logo Current.jpg
Dyadic Announces Change in Board and Management Leadership Roles
March 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic Logo Current.jpg
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 09:57 ET | Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Logo Current.jpg
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 08:30 ET | Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Logo Current.jpg
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic Logo Current.jpg
Dyadic Attends Investor Events in December
November 30, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Attends Investor Events in December
Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic Logo Current.jpg
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023 16:00 ET | Dyadic International, Inc.
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line...
TIP_link_300x300.jpg
Plant-based Vaccines Market Size to Hit 12.9% CAGR, Globally, by 2028 - Exclusive Report by The Insight Partners
November 01, 2023 06:59 ET | The Insight Partners
Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Plants are an important source to produce cost-effective vaccine derivatives. Plant-based vaccines can be made in a cost-effective way and produced on...
Pfizer und BioNTech
Pfizer und BioNTech geben erste positive Daten für mRNA-basiertes Kombinationsimpfstoffprogramm gegen Influenza und COVID-19 bekannt
October 26, 2023 06:45 ET | BioNTech SE
Die in der Phase-1/2-Studie untersuchten führenden Kombi-Impfstoffformulierungen zeigten robuste Immunantworten gegen Influenza A, Influenza B und SARS-CoV-2-Stämme  Das Sicherheitsprofil der...